Crossmark

Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)

Crossref DOI link: https://doi.org/10.1186/s13075-020-02305-w

Published Online: 2020-09-29

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Webers, Casper http://orcid.org/0000-0003-3011-8547
Stolwijk, Carmen

Schiepers, Olga

Schoonbrood, Thea

van Tubergen, Astrid

Landewé, Robert

van der Heijde, Désirée

Boonen, Annelies
Funding

Funding for this research was provided by:

Janssen Biologics
License Information

Text and Data Mining valid from 2020-09-29

Version of Record valid from 2020-09-29
More Information

Article History

Received: 17 March 2020

Accepted: 25 August 2020

First Online: 29 September 2020

Ethics approval and consent to participate

: The ethics committee from the Maastricht University Medical Centre approved this substudy. All patients provided written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below